CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells

Autor: Anne W J Martens, Susanne R Janssen, Ingrid A M Derks, Homer C Adams III, Liat Izhak, Roel van Kampen, Sanne H Tonino, Eric Eldering, Gerritje J W van der Windt, Arnon P Kater

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Background Bispecific antibodies are promising new therapeutics in B cell malignancies. Whether they lead to potent T cell activation despite described T cell dysfunction in chronic lymphocytic leukemia (CLL), and are able to effectively target high-

Externí odkaz: https://doaj.org/article/eca3bcb09fd74a5bb6ade31a029e3358

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837

Autor: Arnon P. Kater, Jaco A. C. van Bruggen, Anne W. J. Martens, Sanne H. Tonino

Publikováno v: Cancers, Vol 13, Iss 4738, p 4738 (2021)

In the original article [...]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fff57a0afd91943d877de461f87752ac
https://www.mdpi.com/2072-6694/13/19/4738

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia

Autor: Sriram Balasubramanian, Arnon P. Kater, Joel Leverson, Gaspard Cretenet, Eric Eldering, Anne W. J. Martens, Erik Slinger

Publikováno v: Blood, 5(23), 5410-5414. American Society of Hematology
Blood advances, 5(23), 5410-5414. American Society of Hematology
Kater, A P, Slinger, E, Cretenet, G, Martens, A W, Balasubramanian, S, Leverson, J D & Eldering, E 2021, ' Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia ', Blood, vol. 5, no. 23, pp. 5410-5414 . https://doi.org/10.1182/bloodadvances.2021004861

The covalent inhibitor of Bruton’s tyrosine kinase ibrutinib and the specific Bcl-2 inhibitor venetoclax are both highly efficacious single-agent drugs in the treatment of chronic lymphocytic leukemia (CLL). Based on their complementary modes of ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d502c1a950ef7af5f14574b7dcd498bf
https://pubmed.ncbi.nlm.nih.gov/34555843

Ligand-dependent downregulation of MR1 cell surface expression

Autor: Natacha Veerapen, David M. Lewinsohn, Mariolina Salio, Anne W. J. Martens, Wael Awad, Corinna Kulicke, Claudia Gonzalez-Lopez, Vincenzo Cerundolo, Dominic Waithe, Judith V. Hobrath, Liam R. Cox, Gurdyal S. Besra, Jamie Rossjohn

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, 117(19), 10465-10475. National Academy of Sciences

Significance MR1 is a monomorphic major histocompatibility complex (MHC) class I-like molecule that presents ligands to Mucosal Associated Invariant T cells. MR1 antigen presentation at the cell surface is tightly regulated by ligand availability. Al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43e8ec78172338967f83c3a2ae2fb5dd

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma

Autor: Arnon P. Kater, Sanne H. Tonino, Anne W. J. Martens, Jaco A. C. van Bruggen

Publikováno v: Cancers
Cancers, Vol 12, Iss 3837, p 3837 (2020)
Cancers, 12(12):3837, 1-31. Multidisciplinary Digital Publishing Institute (MDPI)

Simple Summary The activity of novel therapies that utilize patient’s own T-cells to induce remission of B-cell non-Hodgkin lymphoma (B-NHL), including chronic lymphocytic leukemia (CLL), is still suboptimal. In this review, we summarize the clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41a5e79e19d15a7b70a0959ea45e76ed
https://doi.org/10.3390/cancers12123837